Claus van der Velden Net Worth

Claus van der Velden biography

Dr. Claus van der Velden Ph.D. serves as Independent Director of the Company. He has served as corporate head of Management Accounting, Internal Audit and Risk Management at Stroeer SE & Co KGaA, a publicly listed German digital media company. Previously, Dr. van der Velden served as the Director of Corporate Business Controlling for the Nutrition & Health business unit at Cognis, a worldwide supplier of global nutritional ingredients and specialty chemicals. In this position, he was also a compliance representative and a member of the global leadership team. After the acquisition of Cognis by BASF, he was responsible for the management accounting processes of the BASF Nutrition & Health division, developing and producing mostly natural-source ingredients for the food and healthcare industries. Dr. van der Velden started his career as a strategy consultant at an international marketing and strategy consultancy firm. He studied in Kiel and Stockholm and received a degree in economics from the University of Kiel and later obtained his doctorate in business management from the WHU-Otto Beisheim School of Management where he also previously taught economics.

What is the salary of Claus Velden?

As the Independent Director of Anavex Life Sciences, the total compensation of Claus Velden at Anavex Life Sciences is $109,871. There are 4 executives at Anavex Life Sciences getting paid more, with Christopher Missling having the highest compensation of $3,380,040.

How old is Claus Velden?

Claus Velden is 47, he's been the Independent Director of Anavex Life Sciences since 2018. There are 6 older and 3 younger executives at Anavex Life Sciences. The oldest executive at Anavex Life Sciences Corporation is Stephan Toutain, 55, who is the Chief Operating Officer.

What's Claus Velden's mailing address?

Claus's mailing address filed with the SEC is 630 5TH AVENUE 20TH FLOOR, , NEW YORK, NY, 10111.

Insiders trading at Anavex Life Sciences

Over the last 18 years, insiders at Anavex Life Sciences have traded over $5,238,591 worth of Anavex Life Sciences stock and bought 135,460 units worth $453,776 . The most active insiders traders include Athanasios Skarpelos, Christopher U Missling és Elliot Favus. On average, Anavex Life Sciences executives and independent directors trade stock every 99 days with the average trade being worth of $335,876. The most recent stock trade was executed by Peter D.O. Donhauser on 14 June 2024, trading 2,835 units of AVXL stock currently worth $10,319.

What does Anavex Life Sciences do?

anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.

Anavex Life Sciences executives and stock owners

Anavex Life Sciences executives and other stock owners filed with the SEC include:

• Christopher Missling,
  President, Chief Executive Officer, Secretary, Director
• Dr. Christopher U. Missling,
  Chairman, Pres, CEO & Sec.
• Sandra Boenisch,
  Principal Financial Officer, Treasurer
• Sandra Boenisch CPA, CPA, CGA,
  Principal Financial Officer & Treasurer
• Claus van der Velden,
  Independent Director
• Steffen Thomas,
  Independent Director
• Athanasios Skarpelos,
  Independent Director
• Elliot Favus,
  Independent Director
• Peter Donhauser,
  Independent Director
• Dr. Adebayo Laniyonu Ph.D.,
  Sr. VP of Nonclinical Devel.
• Clint Tomlinson,
  VP of Corp.
• Dr. Walter E. Kaufmann M.D.,
  Chief Medical Officer
• Dr. Emmanuel O. Fadiran RPh, Ph.D.,
  Sr. VP of Regulatory Affairs
• Stephan Toutain,
  Chief Operating Officer
• Bernd Metzner,
  Director
• Jiong Ma,
  Director
• Cameron Durrant,
  Director
• Harvey Lalach,
  President, CFO
• Alison E. Ayers,
  Director
• David L. Tousley,
  Director
• George F Tidmarsh,
  Executive Director
• Panos Kontzalis,
  CEO
• George Kalkanis,
  VP Strategic Planning
• Angela Vernadaki,
  VP Business Development